Proving a biosimilar's pharmacokinetic 'equivalence' requires adherence to several unique factors.
Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Articles by Yvonne Moores, Executive Vice President, Operations (SRBU), Quanticate
Advertisement
Latest Updated Articles
Demonstrating Biosimilarity: PK ConsiderationsPublished: October 1st 2014 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
3
AI in Action: Breaking Down Clinical Trial Bottlenecks
4
Focusing on Site Needs and Challenges: Quick Tips for Sponsors/CROs
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
